Q1 Earnings Estimate for Alkermes Issued By Zacks Research

Alkermes plc (NASDAQ:ALKS) – Equities research analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for shares of Alkermes in a report issued on Wednesday, April 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.28 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.33 EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.43 EPS, FY2026 earnings at $1.24 EPS and FY2027 earnings at $1.14 EPS.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Several other analysts also recently weighed in on ALKS. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Royal Bank of Canada initiated coverage on shares of Alkermes in a report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 price objective on the stock. Finally, HC Wainwright reiterated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.50.

Alkermes Price Performance

Alkermes stock opened at $27.00 on Monday. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 12.44, a P/E/G ratio of 2.20 and a beta of 0.39. The firm has a fifty day moving average price of $33.14 and a two-hundred day moving average price of $30.47. Alkermes has a fifty-two week low of $22.90 and a fifty-two week high of $36.45.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 100,918 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total value of $3,234,421.90. Following the transaction, the executive vice president now directly owns 44,290 shares of the company’s stock, valued at $1,419,494.50. The trade was a 69.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in shares of Alkermes during the third quarter worth approximately $437,000. Orion Portfolio Solutions LLC acquired a new stake in Alkermes during the 3rd quarter worth $264,000. Barclays PLC raised its position in shares of Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after acquiring an additional 220,893 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Alkermes by 254.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock valued at $944,000 after purchasing an additional 23,541 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Alkermes in the 3rd quarter valued at $582,000. 95.21% of the stock is currently owned by institutional investors and hedge funds.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.